China CDMO (Contract Development & Manufacturing Organization) Industry Research Report, 2018-2021

Publisher Name :
Date: 10-Jul-2018
No. of pages: 80

China's pharmaceutical R&D industry started late, with insufficient technical capacity and fewer investment at the initial stage of development. However, it has achieved rapid development in recent years and has great room for improvement. In 2017, China invested approximately US $13.2 billion in medical R&D, accounting for 8.9 percent of the total global medical R&D investment in the same period. With the improvement of Chinese drug firms’ R&D strength and the strengthening of government control of generic drugs, such as development of the generic consistency evaluation, the clinical trial data of audits and inspections, etc., the Chinese pharmaceutical R&D spending will continue to increase. China's pharmaceutical R&D spending is expected to reach US $29.2 billion in 2021, accounting for the total amount of the global pharmaceutical R&D spending will rise to 18.3%.

The global market for drug development services reached about US $71.7 billion in 2017.At a time when the cost of developing new drugs is high and generic competition is fierce around the world, pharmaceutical companies are increasingly inclined to outsource drug development to speed up the development of new drugs. The global market for drug development services is expected to grow to US $102.8 billion by 2021.

Compared with the global pharmaceutical development service market, the volume of China's pharmaceutical development service market is small, but the growth is fast. In 2017, China's drug development services market size reached approximately US $79.2 billion, and is expected to increase by 2021 to $27.8 billion.

CDMO market is developing rapidly in recent years, it is a highly fragmented industry, full of market competition. The world's leading CDMO company mainly include catalent, patheon, Lonza, BI, Jubilant, top CDMO enterprises currently accounts for the overall market share of about 18%.

In recent years, along with the great progress of China and India in talent cultivation, pharmaceutical technology research, especially in China, which has complete infrastructure, adequate raw material supply and significant operating cost advantage, these areas gradually become the CDMO emerging markets. Currently the CDMO business is transforming from developed markets to emerging markets, the CDMO market share of Europe and the United State has decreased from 75% in 2010 to 67% at present. Countries such as China and India has improved their market share from 10% to 15% at present, with China's market share accounted for about 8%.

Similar to the international market competition, China’s CDMO overall market concentration is low at present, part of the CDMO players with comprehensive competitiveness such as Asymchem, STA Pharmaceutical, WuXi Biologics and Porton Fine Chemicals etc., has higher market share., but there is still no absolute leading enterprises.

China CDMO (Contract Development & Manufacturing Organization) Industry Research Report, 2018-2021

Table of Contents

1. Overview of Contract Development & Manufacturing Organization
1.1 Definition
1.2 Mainstream Technologies
1.2.1 Asymmetric synthesis
1.2.2 Cryogenic reaction
1.2.3 Enzymic catalytic reaction
1.2.4 High temperature and high pressure reaction
1.2.5 Crystallization technologies
1.2.6 High activity laboratory
1.3 Industry Chain

2. Policy
2.1 Snapshot of Policies
2.2 Chinese Pharmaceutical Marketing Authorisation Holder System (MAH)

3. Background of CDMO Industry
3.1 Development of Global Pharmaceuticals Industry
The global pharmaceutical industry has huge market space,with stable future growth
Europe and the United States remain the world's largest pharmaceutical market
China's future global market share will gradually increase
Drivers of Global Pharmaceuticals Industry
3.2 Why CDMO?-Reasons for the rise
The R&D cost of new drugs continues to rise while the success rate decreases year by year
Biotech companies are on the rise
Strong returns on patented drugs and pressure on patent expiry have prompted drug companies to step up R&D of new drugs
Chemical drugs remains dominate, the number of micromolecule new drugs is on the rise
3.3 Trends of global pharmaceutical market
The importance of emerging markets are increasing
The share of patented innovative drugs will continue to increase
Innovative biotechnology r&d companies continue to develop
Micromolecule chemical drugs will remain a key area of R&D for some time to come
3.4 Trends of China pharmaceutical market
The popularity of generic drugs has declined and new drugs R&D are on the rise
The pharmaceutical industry has become more innovative and small biotech companies have sprung up

4 CDMO Market
4.1 Entire Pharmaceutical Outsourcing Market
4.2 CRO Market
4.3 CDMO market
4.4 Market Landscape
4.5 Review of CDMO M&A

6 CDMO Players in China
6.1 Asymchem Laboratories (Tianjin) Co., Ltd.
6.1.1 Profile
6.1.2 Technology
6.1.3 Capacity
6.1.4 Projects
6.2 WuXi Biologics (Cayman) Inc.
6.2.1 Profile
6.2.2 Capacity
6.2.2 Projects
6.3 STA Pharmaceutical Co. Ltd.
6.3.1 Profile
6.3.2 Technology
6.3.3 Capacity
6.4 Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
6.4.1 Profile
6.4.2 Technology
6.4.2 Projects
6.5 3SBio Inc.
6.5.1 Profile
6.5.2 Technology
6.5.3 Manufacturing
6.5.4 CDMO for antibody drugs
6.6 Porton Fine Chemicals Ltd.
6.6.1 Profile
6.6.2 Technology
6.6.3 Capacity
6.6.4 Projects
6.7 Lianhe Chemical Technology Co., Ltd.
6.7.1 Profile
6.7.2 Technology
6.7.2 CDMO Business
6.8 Laviana Pharma Co., Ltd.
6.8.1 Profile
6.8.2 Technology
6.8.3 Capacity
6.9 Pharmaron Beijing Co., Ltd.
6.9.1 Profile
6.9.2 Technology
6.9.3 Capacity
6.9.3 CDMO Business
6.10 PharmaResources (Shanghai) Co., Ltd.
6.10.1 Profile
6.10.2 CDMO Business
6.11 Shanghai ChemPartner Co., Ltd.
6.11.1 Profile
6.11.2 CDMO Business

7 Industry Development Trends
7.1 Integrated Industry Chain
Porton Fine Chemicals Ltd.-Expanding CDMO business to upstream CRO business
STA Pharmaceutical Co. Ltd. - Expanding CDMO business to downstream pharmaceutics
7.2 Bio-pharmaceutical CDMO-Main battlefield in the future

List of Charts

Service links of CDMO in pharmaceutical production & research process
Service content of CDMO in pharmaceutical production & research process
Value chain of CDMO Industry
CDMO business models
Policies of China CRO&CDMO Industry, 2010-2017
Global Pharmaceuticals Industry Market Sizez by Segment, 2012-2021E
Global Pharmaceuticals Industry Market Sizez by Region, 2012-2021E
China Pharmaceuticals Industry Market Sizez by Segment, 2012-2021E
The total cost of health care in China,2011-2017
Total global health care costs,2011-2015
The scale of venture capital in China and the global pharmaceutical sector,2013-2016
The average cost of a new drug from development to approval
Cumulative success rate from phase I to phase III of new drug development
The number of drugs at each stage of development, 2016/2017
The number of global biotech IPOs and the amount raised,2011-2015
Number of CDE class I chemical new drugs application, 2013-2017
Number of CDE class I biological new drugs application, 2013-2017
Overview of some IND declaration companies in China
Average NAS sales in the United States after the drug was marketed,1996-2015
Global pipeline for drug development,2001-2017
The number of new drugs approved by FDA, 2001-2017
Number of global micromolecule new drugs under different R&D stages, 2012-2017
Number of micromolecule new drug projects access next stage, 2012-2017
Pineline share of biological and non-biological drugs under R&D, 1995-2017
Global and China pharmaceutical R&D investment, 2012-2021E
Global CRO +CDMO market size, 2012-2021E
China CRO +CDMO market size, 2012-2021E
Global CRO market size, 2012-2021E
China CRO market size, 2012-2021E
Global CDMO market size, 2012-2021E
China CDMO market size, 2012-2021E
Market share of global TOP5 CDMO enterprises, 2017
Regional market share of global CDMO industry, 2017
Global CDMO market relative cost comparison by region
Revenue CAGR of some Global DCMO enterprises, 2013-2017
Market share of Chinese CDMO enterprises, 2017
Revenue CAGR of some Chinese DCMO enterprises, 2013-2017
Capacity of global CMO companies, 2017
Top 2017 CDMO M&A Headlines
Major CDMO market M&A, 2014-2017
Ownership Structure of ASYMCHEM
Business scope of ASYMCHEM
Core technology of ASYMCHEM
R&D investment of ASYMCHEM, 2013-2017
Organization structure of ASYMCHEM Pharmaceutical Science and Technology Institute
Domestic revenue share of ASYMCHEM, 2011-2017
Facilities of ASYMCHEM
Capacity of ASYMCHEM
Revenue structure of ASYMCHEM (by product), 2013-2017
Reserve projects of ASYMCHEM (by product), 2013-2017
Innovative drugs in ASYMCHEM’s commercial projects
Penem antibiotics capacity of Tianjin Asymchem Pharmaceuticals Co., Ltd.
Expansion plan of ASYMCHEM
Capacity addition plan of WuXi Biologics
Backlog increased to US$476mn, with additional US$1.0bn in potential milestones
There has been a constant inflow of projects and customers in the last few months
WuXi Biologics recorded a significant increase in project numbers
Ownership structure of STA Pharmaceutical
Revenue Structure of STA Pharmaceutical (by product), 2012-2017
CDMO business model of STA Pharmaceutical
Production and Sales of Jiuzhou Pharmaceutical’s CDMO business, 2015-2017
CDMO projects of Jiuzhou Pharmaceutical till 2017
History and key milestones of 3SBio Inc.
Key Therapeutic Areas & Capability Focus of 3SBio Inc.
R&D center structure of 3SBio Inc.
R&D platform of 3SBio Inc.
R&D process of 3SBio Inc.
Manufacturing bases of 3SBio Inc.
key information for each production line of 3SBio’s CDMO platform
New drug R&D services of 3SBio’s CDMO platform
CDMO capabilities of 3SBio
Services of Porton by drug life cycle
CDMO revenue of Porton, 2013-2017
Pilot-Scale & Commercial-Scale Manufacture sites of Porton
Pre-production products of Porton’s bio-pharmaceutical CDMO project
Top5 clients of Laviana Pharma, 2015-2017
Ownership structure of Pharmaron
Strucure of Pharmaron’s R&D department
CDMO capacity of Pharmaron, 2015-2017
Services of Pharmaron’s CRO&CDMO business platform
Revenue and gross margin of Pharmaron’s CDMO business, 2015-2017
Number of clients and projects of Pharmaron’s CDMO business, 2015-2017
Ownership structure of PharmaResources
TOP5 Clients of PharmaResources, 2015-2017
CDMO Revenue of PharmaResources, 2015-2017
Classificaiton of Shanghai ChemPartner’s CDMO business
CDMO revenue and gross margin of Shanghai ChemPartner, 2015-2017
Business chain expand of Porton Fine Chemicals Ltd.
Business chain expand of STA Pharmaceutical Co. Ltd.
Bio-pharmaceutical share in global new drugs under R&D, 2012-2017
Competitive landscape of global bio-pharmaceutical market, 2017
Revenue of Samsung Biologics (by business), 2014-2017
Capacity of Samsung Biologics, 2013-2018E (‘0000 litre)
Capacity of Samsung Biologics by plant
Utilisation rate forecasts by each plant of Samsung Biologics, 2014-2022E

  • Global Vinpocetine Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 135
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vinpocetine Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 128
    Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine, an extract from the lesser periwinkle plant. Vinpocetine was first isolated from the plant in 1975 by the Hungarian chemist Csaba Szántay. The mass production of the synthetic compound was started in 1978 by the Hungarian pharmaceutical company Richter Gedeon. The indications is improvement all symptoms of cerebral infarction and cerebral hemorrhage sequela, cerebrovascular atherosclerosis Scope of the Report:......
  • Global Bone Morphogenetic Protein (BMP) 2 Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 117
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bone Morphogenetic Protein (BMP) 2 Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 115
    Bone morphogenetic proteins (BMPs) are naturally occurring proteins found in the human body. This family of proteins is involved in a myriad of cellular responses. Certain BMPs are osteoinductive—one of the three main categories of bone grafts—and play an active role in bone formation and maintenance. Scope of the Report: This report focuses on the Bone Morphogenetic Protein (BMP) 2 in global market, especially in North America, Europe and Asia-Pacific, South America, Middl......
  • Global Bacillus Coagulans Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Jul-2018        Price: US 3480 Onwards        Pages: 137
    Bacillus Coagulans is a lactic acid-forming bacterial species within the genus Bacillus. The organism was first isolated and described as Bacillus Coagulans in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensary. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual, it exhibits characteristics typical of both genera Lactobacillus and Bacill......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Bacillus Coagulans Market 2018, Forecast to 2023
    Published: 17-Jul-2018        Price: US 4880 Onwards        Pages: 133
    Bacillus Coagulans is a lactic acid-forming bacterial species within the genus Bacillus. The organism was first isolated and described as Bacillus Coagulans in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensary. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual, it exhibits characteristics typical of both genera Lactobacillus and Bacill......
  • Global Pulmonary Drugs Market Research Report 2018
    Published: 16-Jul-2018        Price: US 2900 Onwards        Pages: 99
    This report studies the global Pulmonary Drugs market status and forecast, categorizes the global Pulmonary Drugs market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Pulmonary Drugs market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The ......
  • Global Hemostatic Agents Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Jul-2018        Price: US 3480 Onwards        Pages: 146
    Hemostatic agents are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: This report focuses on the Hemostatic Agents in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Hemostatic Agents is expected to grow at a CAGR o......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Hemostatic Agents Market 2018, Forecast to 2023
    Published: 16-Jul-2018        Price: US 4880 Onwards        Pages: 154
    Hemostatic agents are used as an adjunct or alternative to standard suturing techniques to control bleeding or for wound closure. Scope of the Report: This report focuses on the Hemostatic Agents in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Hemostatic Agents is expected to grow at a CAGR o......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs